Shahram Seyedin-Noor is a venture capital investor at Civilization Ventures who combines an unusual background as a Harvard-trained lawyer, Goldman Sachs investment banker, and serial biotech founder-operator, having been founding CEO of oncology company Inspirna and CFO at genomics software company NextBio before becoming a VC. He deliberately built Civilization Ventures as a small, operator-led fund that focuses on backing young, unorthodox first-time technical founders in overlooked areas like genomics and AI in biotech, providing hands-on mentor capital from day zero rather than following traditional biotech VC pattern recognition.

• A rigorous standard for biotechnology investments, prioritizing hard scientific evidence over hype. He emphasizes that for bio-startups, anything other than solid intellectual property and animal data is merely a vanity metric, and he likens the difficulty of succeeding in this sector to winning a marathon at high altitude.
• Belief that artificial intelligence is now a mandatory requirement for startups rather than an optional add-on. He regards AI as table stakes for narrative building, explicitly stating that companies, even in the bio and health sectors, face obsolescence if AI is not central to their story.
• High expectations for communication speed and operational intensity. He uses email responsiveness as a proxy for professional caliber, suggesting that A+ players reply to almost all emails within 24 hours, viewing speed as a critical competitive advantage.
• Support for founder-led vision over venture capitalist theses. He criticizes investors who expect founders to merely execute on a VC's theory, arguing that the best companies are built by founders finding their own path to product-market fit rather than dutifully following an investor's roadmap.
• Interest in the longevity and anti-aging market, balanced with skepticism toward unproven trends. While he predicts major advancements in human health extension over the next decade, he warns founders and consumers against getting swept up in unverified crazes, such as the use of unproven peptides without sufficient evidence.
• Focus on decisive leadership and talent management. He advises founders to be swift in firing non-performers, noting that being too nice to underperforming employees puts the founder at risk of being fired by their own customers or stakeholders.